Sweden: A national case-control study from Sweden found that women vaccinated against human papillomavirus (HPV) had significantly lower risks of preterm, very preterm, and spontaneous preterm birth. The protective associations were stronger among women vaccinated before age 17. However, adjustment for high-grade cervical lesions before childbirth weakened these associations, suggesting that cervical lesions may partly explain the observed relationship.              

Published in The BMJ, the study was conducted by Zhongsong Zhang, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden, and colleagues. The researchers investigated whether quadrivalent HPV (qHPV) vaccination received before pregnancy was associated with subsequent pregnancy outcomes.
HPV vaccination is primarily used to prevent HPV-related cancers. However, previous evidence has linked HPV infections and the treatment of cervical lesions with an increased risk of adverse pregnancy outcomes. Earlier studies examining whether vaccination could reduce these risks were limited by a lack of nationwide data and adequate adjustment for confounding factors.
For the study, researchers analysed 624,713 singleton births among nulliparous women aged 16–35 years in Sweden between 2006 and 2023. Of these, 92,620 women (14.8%) had received qHPV vaccination before pregnancy. Using a nationwide, population-based matched case-control design, the team assessed preterm birth before 37 weeks, its subtypes, and spontaneous preterm birth as primary outcomes. Other outcomes included premature rupture of membranes, small-for-gestational-age infants, stillbirth, and neonatal mortality. Cases and controls were matched for maternal age at birth and calendar year of conception.
The analysis revealed the following findings:
  • Preterm birth: Vaccination was associated with 5% lower adjusted odds of birth before 37 weeks (adjusted odds ratio [aOR] 0.95).
  • Very preterm birth: The adjusted odds were 15% lower for births between 28 and 31 weeks (aOR 0.85).
  • Spontaneous preterm birth: Vaccinated women had 5% lower adjusted odds (aOR 0.95).
  • Other pregnancy outcomes: Vaccination was associated with lower odds of preterm prelabour rupture of membranes (aOR 0.93) and severe small-for-gestational-age birth, defined as birth weight below the third centile (aOR 0.92).
  • Age at vaccination: Risk reductions were generally more pronounced among women vaccinated at younger ages.
The study’s observational design limits causal conclusions, and residual confounding from vaccination uptake, HPV exposure, health-seeking behaviour and reproductive factors cannot be ruled out. Lack of data on post-vaccination HPV infections and cervical treatments also limited assessment of underlying mechanisms. Rare outcomes, including stillbirth and neonatal mortality, had limited statistical power.
The findings suggest that HPV vaccination may reduce certain adverse pregnancy outcomes beyond its established cancer-prevention benefits. The researchers emphasised timely school-based vaccination and recommended including potential reproductive benefits in future policy and cost-effectiveness evaluations.
Reference:
BMJ 2026;395:e100739
Tags:    
Article Source : The BMJ

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate complex research into clear, accessible information for healthcare professionals.

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .